Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Questions J&J/Merck OTC Joint Venture's Manufacturing Practices

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson and Merck attract undesired FDA attention - a letter identifying good manufacturing practice problems with the firms' OTC joint venture
Advertisement

Related Content

Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
McNeil Recalls Cut J&J's Profits, Draw U.S. Attorney's Subpoena
McNeil Recalls Cut J&J's Profits, Draw U.S. Attorney's Subpoena
McNeil Recalls Cut J&J's Profits, Draw U.S. Attorney's Subpoena
McNeil Recalls Cut J&J's Profits, Draw U.S. Attorney's Subpoena

Topics

Advertisement
UsernamePublicRestriction

Register

PS104334

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel